Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews · Metabolic and Endocrine Disorders

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 100%High 0 · 0%

Serious adverse events (n/N)

Summary of findings: insulin detemir showed no clear difference in serious adverse events (n/N) compared with NPH insulin (moderate certainty).

1 finding from 1 review

(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
RR 0.95 [0.75, 1.21]
9 studies · 3332 participants
Moderate

Serious adverse events (n/N)

Summary of findings: insulin glargine showed no clear difference in serious adverse events (n/N) compared with NPH insulin (moderate certainty).

1 finding from 1 review

(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
RR 1.08 [0.63, 1.84]
8 studies · 2229 participants
Moderate